A Phase 1 Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Patients With Hepatic Impairment and Healthy Matched Controls

Cabotegravir is an investigational integrase inhibitor in development for the treatment and pre‐exposure prophylaxis of HIV‐1 infection. Liver disease is a major cause of morbidity and mortality in HIV‐infected individuals and can impact the pharmacokinetics (PK) of HIV medications. This phase 1 stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Shaik, Jafar Sadik B., Ford, Susan L., Lou, Yu, Zhang, Zhiping, Bakshi, Kalpana K., Tenorio, Allan R., Trezza, Christine, Spreen, William R., Patel, Parul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619238/
https://www.ncbi.nlm.nih.gov/pubmed/30811880
http://dx.doi.org/10.1002/cpdd.655

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6619238/
https://www.ncbi.nlm.nih.gov/pubmed/30811880
http://dx.doi.org/10.1002/cpdd.655

Ejemplares similares